An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies DevelopmentJochem Gokemeijer, Vibha Jawa, Sophie Tourdot et al.|Clinical Pharmacology & Therapeutics|2023Cited by 9
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ ConsortiumJoanna Grudzinska‐Goebel, Vibha Jawa, Linzhi Chen et al.|Nucleic Acid Therapeutics|2025Cited by 6